Evaluation of the Absorption of a Sublingual Semaglutide Compounded Formulation
(SubMagnaTM SL HMW) using the EpiGingivalTM and EpiOralTM In Vitro Tissue Models
SUMMARY: GLP-1 agonists have been increasingly utilized in the treatment of type 2 diabetes and obesity. The
semaglutide commercial oral tablets have extremely low absorption and an alternative sublingual compounded
formulation is proposed: semaglutide in SubMagna SL HMW. The in vitro tissue models suggest that SubMagna
SL HMW is able to deliver the peptide into and through human gingival and oral tissues.
Evaluation of the Absorption of a Sublingual Semaglutide Compounded Formulation
(SubMagnaTM SL HMW) using the EpiGingivalTM and EpiOralTM In Vitro Tissue Models
This in vitro study demonstrates that
SubMagna SL HMW is able to deliver the peptide into
and through human gingival and oral tissues.
Evaluation of SubMagnaTM SL HMW Liposomal Formation
Using Fluorescence Microscopy
SUMMARY: Green fluorescent protein (GFP) was used in this study to mimic the peptide semaglutide. When
GFP is incorporated in SugMagna and the formulation is exposed to water, there is spontaneous formation
of liposomes which is a favorable attribute for the delivery of medications.